Post by
ScienceFirst on Mar 07, 2023 10:42am
Roche is my take as our NMIBC jv partner
Pfizer and Merck seem to have other plans. At least, for what we've seen in their strategic plans recently announced. Doesn't mean the door is completely closed though.
Roche has failed in entering the bladder cancer indication. They would have a golden opportunity to re-enter this important market.
Roche is also in the 3 fields that we're aiming; urology, neurology and pulmonary.
Roche is bigger than Pfizer and Merck.
Comment by
Rumpl3StiltSkin on Mar 07, 2023 11:17am
I like the idea of Roche.
Comment by
N0taP00p on Mar 07, 2023 3:16pm
Novartis could be another. They have their Keytruda equivalent blockbuster in Gleevec and their CEO has indicated they are looking out for early stage companies to buy or partner with. Opens all kinds of doors after BTD. At least, the dependence on retail investors will no longer be a crutch. Two months max to find out, I guess.